News

XTANDI® (enzalutamide) Receives Health Canada Approval as the First and Only Treatment for High-Risk Patients with Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) MARKHAM, ON, January 30, 2024 – Today, Astellas Pharma Canada, Inc. announced that Health Canada has approved a supplemental New Drug Application for XTANDI® (enzalutamide) in a new prostate cancer treatment setting. With...

XTANDI is the only treatment approved for three clinical disease states across four indications, and the improved access for mCSPC patients will support earlier treatment MARKHAM, ON, June 23, 2022 /CNW/ - Astellas Pharma Canada, Inc., announces that XTANDI® (enzalutamide), an oral once-daily therapy, 1 is now reimbursed across most of Canada for the treatment of patients with metastatic...

MARKHAM, ON, April 29, 2022 – Astellas Pharma Canada, Inc., a leader in innovative medicines headquartered in Markham, Ontario recognizes the Ontario government for the commitment of $15-million over three years for the new Life Sciences Innovation Program outlined in the Spring Budget. "Our vision at Astellas is to stand on the forefront of healthcare change, turning innovative science into value...

Astellas ranked 47 th on the Best Workplaces™ in Canada list MARKHAM, ON, April 27, 2022 – Astellas Pharma Canada, Inc. has been named again on the list of Best Workplaces™ in Canada by the Great Place to Work® Institute, marking the seventh year in a row to receive this recognition. The Institute honours employers across the country who create and foster exemplary workplaces. This year Astellas...

Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. MARKHAM, ON, April 21, 2022 /CNW/ - Astellas Pharma Canada, Inc., announces today on World AML Day, that Alberta 1 , British Columbia 2 , Manitoba 3 , New Brunswick 4 , Newfoundland and Labrador 5 , Nova Scotia 6 , Ontario 7...